US Patent Issued to SHANGHAI HENLIUS BIOTECH, SHANGHAI HENLIUS BIOPHARMACEUTICAL, SHANGHAI HENLIUS BIOLOGICS on April 21 for "Methods and compositions for anti-CD73 antibodies and variants" (Chinese Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,633, issued on April 21, was assigned to SHANGHAI HENLIUS BIOTECH INC. (Shanghai), SHANGHAI HENLIUS BIOPHARMACEUTICAL Co. LTD. (Shanghai) and SHANGHAI HENLIUS BIOLOGICS Co. LTD. (Shanghai).

"Methods and compositions for anti-CD73 antibodies and variants" was invented by Wei-Dong Jiang (Shanghai), I-yin Chen (Shanghai) and Chi-Ling Tseng (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are anti-CD73 antibodies, variants, and antigen binding fragments thereof. The antibodies, the variants, and the antigen binding fragments thereof bind to human CD73 with high affinity, and suppress the enzymatic activity of CD73, and optionally induc...